Research programme: virus-like particles - Agilvax

Drug Profile

Research programme: virus-like particles - Agilvax

Alternative Names: AX 03; Breast cancer immunotherapy - Agilvax; Dengue vaccine - Agilvax; Human papilloma virus vaccine - Agilvax; Malaria vaccine - Agilvax; Non-Hodgkin's lymphoma immunotherapy - Agilvax; Ovarian cancer immunotherapy - Agilvax; Pan-Ebola vaccine - Agilvax; Pan-Filovirus vaccine - Agilvax; Respiratory syncytial virus vaccine - Agilvax

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Agilvax
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunogenetic stimulants; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Dengue; Human papillomavirus infections; Malaria; Non-Hodgkin's lymphoma; Ovarian cancer; Respiratory syncytial virus infections
  • Research Ebola virus infections; Viral haemorrhagic fevers

Most Recent Events

  • 06 Sep 2016 Agilvax receives patent allowance for human papillomavirus vaccine candidate in USA
  • 28 Jul 2016 Agilvax receives SBIR grant from National Institute of Allergy and Infectious Diseases (NIAID) for virus-like particles based vaccine development in Respiratory syncytial virus infections
  • 29 Feb 2016 Agilvax receives Notice of Allowance from USPTO an Intention to Grant in European Patent Application from EPO for virus-like particles in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top